Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma.
A new blood test predicts how multiple myeloma will progress in individual patients, helping doctors tailor treatment intensity upfront.
PURPOSE: While survival outcomes in multiple myeloma (MM) have improved with contemporary combination therapies, predicting disease trajectories for individual patients at diagnosis remains a significant challenge. The wp-score showed strong prognostic ability for OS (hazard ratio [HR], 2.9 [95% CI, 1.7 to 4.9]; P < .0001) and PFS (HR, 1.8 [95% CI, 1.3 to 2.5] P = .00014) in the validation set, controlling for known prognostic fact...
What the study was
- Study design
- Cohort study
- Population
- patients
- Sample size
- 321
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- JCO precision oncology
Why it surfaced
Score 6/10 [EARLY_CANCER_DETECTION]: Cohort study (Journal Article) matched 'Early cancer detection (liquid biopsy, c'. Components — novelty:1/3, relevance:2/3, design:1/2, population:2/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.